Voriconazole: A second-generation triazole

Drugs of Today

Volumn 37, Issue 2, 2001, Pages 135-148

  Chandrasekar, P H ^a   Manavathu, E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PATIENT MONITORING; RASH; REVIEW; STEADY STATE;

EID: 0035073834     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.2.614849     Document Type: Review

References (90)

1. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Synthesis and SAR
2. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of systemic fungal infections: Discovery and antifungal properties
3. Novel analogs of SCH 51048: Synthesis and preliminary structure activity relationships
4. SCH 56592, a novel broad spectrum antifungal agent
5. Modeling of cytochrome P450 14α-demethylase (Candida albicans) from P450cam
6. Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase (CYP51) from azole resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents
7. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
8. Metabolism of sterols in yeast
9. Sterol structure and membrane function
10. Evidence for dual physiological forms of ergosterol in Saccharomyces cerevisiae
11. Multiple functions for sterols in Saccharomyces cerevisiae
12. Sterol synergism in yeast
13. Structural and physiological features of sterols necessary to satisfy bulk membrane and sparking requirements in yeast sterol auxotrophs
14. Biochemical targets for antifungal azole derivatives: Hypothesis on the mode of action
15. Yeast cytochrome P-450 catalyzing lanosterol 14α-demethylation
16. Active site topology of Saccharomyces cerevisiae lanosterol 14α-demethylase (Cyp51) and its G301 mutant (cytochrome P-4503G1)
17. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
18. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
19. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole
20. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
21. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia
22. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
23. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: In vitro efficacy compared with that of itraconazole and ketoconazole
24. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
25. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
26. In vitro evaluation of voriconazole against some clinically important fungi
27. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
28. In vitro susceptibility of the seven Malassezia species to voriconazole, terbinafine, ketoconazole and itraconazole
29. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
30. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole and amphotericin B
31. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less common mold pathogens
32. In vitro activity of the new triazole BMS-207147 against Aspergillus species
33. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
34. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
35. A comparative study of the broth micro- and macrodilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus
36. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
37. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
38. Organism-dependent fungicidal activity of azoles
39. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
40. A comparative study of the susceptibility of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
41. Modulation of fluconazole sensitivity by the interaction of mitochondria and Erg3p in Saccharomyces cerevisiae
42. Molecular analysis of cys51 from fluconazole-resistant Candida albicans strains
43. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
44. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
45. Reduced susceptibility of fluconazole-resistant clinical isolates of Candida albicans to voriconazole
46. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus species to amphotericin B, itraconazole, voriconazole and posaconazole (SCH56592)
47. In vitro susceptibility of itraconazole-resistant isolates of Aspergillus fumigatus to voriconazole
48. Isolation and in vitro susceptibility to amphotericin B (AMB), itraconazole (ITZ) and SCH56592 (SCH) of voriconazole (VCZ)-resistant laboratory isolates of Aspergillus fumigatus
49. Current and emerging azole antifungal agents
50. Progress in the search for new triazole antifungal agents
51. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
52. Potential new antifungal agents
53. Treatment of fluconazole- resistant candidiasis with voriconazole in patients with AIDS
54. New drugs and novel targets for the treatment of invasive fungal infections in patients with cancer
55. UK-109,496, a novel, wide-spread triazole derivative for the treatment of fungal infections: Disposition in man
56. Voriconazole: A new antifungal
57. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in animals
58. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC)
59. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Aspergillus
60. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea pig mode
61. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
62. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Preclinical pharmacokinetics
63. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in experimental model of invasive pulmonary aspergillosis
64. Efficacy of UK-109496, a new triazole antifungal agent, in an experimental model of invasive aspergillosis
65. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Cryptococcus
66. Voriconazole vs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial
67. Efficacy and safety of voriconazole in the treatment of invasive fungal infection in children
68. Voriconazole for the treatment of resistant and rare fungal pathogens
69. Voriconazole for the treatment of S. apiospermum and S. prolificans infections
70. Skull base osteitis following fungal sinusitis
71. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia
72. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: Cure with voriconazole
73. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
74. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
75. Meningitis caused by Pseudallescheria boydii treated with voriconazole
76. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity and selectivity in vitro
77. The effect of voriconazole on the pharmacokinetics of cyclosporin
78. The pharmacokinetics of voriconazole and its effect on prednisolone disposition
79. Effects of rifampin and rifabutin on the pharmacokinetics of voriconazole
80. Drug interactions between voriconazole and phenytoin
81. Effect of omeprazole on the pharmacokinetics of voriconazole
82. Voriconazole potentiates the warfarin-induced prolongation of prothrombin time
83. Voriconazole does not affect the pharmacokinetics of digoxin
84. No significant pharmacokinetic interactions between voriconazole and indinavir
85. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates
86. A double-blind, randomized, multicenter trial of voriconazole vs fluconazole for the treatment of esophageal candidiasis in immunocompromised adults
87. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
88. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections. Clinical efficacy in chronic invasive aspergillosis - Interim analysis results